Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cloricromen
- Development stage
- Unknown
- Lead developer
- Olon
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Cloricromen is a synthetic small molecule belonging to the coumarin class, specifically a derivative of coumarins and phenylpropanoids. It acts as an antithrombotic agent and platelet aggregation inhibitor, primarily used for its ability to inhibit platelet aggregation in humans and experimental models. Its mechanism involves antagonizing or impairing pathways leading to blood platelet aggregation, which may include interference with activation phases or prostaglandin-thromboxane system signaling. In addition to its antiplatelet effects, preclinical studies suggest potential anti-inflammatory properties through reduction of tumor necrosis factor-alpha (TNF-alpha) production at the pre-transcriptional level. It has been investigated for use in conditions such as thrombosis, periodontitis (in animal models), ischemic retinal diseases, and cerebrovascular occlusive disease; however, clinical efficacy in some indications remains unproven[3][4][6][8].
- Brand names
- ProendotelCromocap
- Other names
- CloricromeneCloricromenumCloricromeno8-chlorocarbochromen
Beyond the preview
Go deeper on cloricromen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cloricromen.